Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Laguna

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 23, 2022
HDL Lipoproteins: A fluid and changing relationship between quantity and functionalityJuan Carlos Laguna Egea
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 3, 2014
[From bench to bed side:a splendid route fraught with difficulties]Juan Carlos Laguna Egea
Med (New York, N.Y.)|April 13, 2024
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 studyJuan Carlos Laguna, Laura Mezquita
Nutrients|December 24, 2014
Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insightJuan Carlos Laguna, Marta Alegret, Núria Roglans
Current Opinion in Lipidology|March 21, 2023
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of actionNúria Roglans, Juan Carlos Laguna, Marta Alegret
Medicina Clinica|October 15, 2011
[Drug-facilitated crime: improving coordination]Alexandre Xifró, Eneko Barbería, Carlos Laguna, et al.
Medicina Clinica|September 18, 2012
[Reply]Alexandre Xifró, Eneko Barbería, Carlos Laguna, et al.
Nutrients|February 27, 2026
A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy InnovationYanhao Qiu, Juan Carlos Laguna, Marta Alegret, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|May 27, 2023
Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset
Endocrinology|April 2, 2005
Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cellsMireia Jové, Anna Planavila, Juan Carlos Laguna, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|June 23, 2022
HDL Lipoproteins: A fluid and changing relationship between quantity and functionalityJuan Carlos Laguna Egea
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|December 3, 2014
[From bench to bed side:a splendid route fraught with difficulties]Juan Carlos Laguna Egea
Med (New York, N.Y.)|April 13, 2024
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 studyJuan Carlos Laguna, Laura Mezquita
Nutrients|December 24, 2014
Simple sugar intake and hepatocellular carcinoma: epidemiological and mechanistic insightJuan Carlos Laguna, Marta Alegret, Núria Roglans
Current Opinion in Lipidology|March 21, 2023
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of actionNúria Roglans, Juan Carlos Laguna, Marta Alegret
Medicina Clinica|October 15, 2011
[Drug-facilitated crime: improving coordination]Alexandre Xifró, Eneko Barbería, Carlos Laguna, et al.
Medicina Clinica|September 18, 2012
[Reply]Alexandre Xifró, Eneko Barbería, Carlos Laguna, et al.
Nutrients|February 27, 2026
A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy InnovationYanhao Qiu, Juan Carlos Laguna, Marta Alegret, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|May 27, 2023
Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset
Endocrinology|April 2, 2005
Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cellsMireia Jové, Anna Planavila, Juan Carlos Laguna, et al.
Pageof 7